Lonza plans to invest approximately CHF 500 million to upgrade the facility
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
The drug will target specific genetic mutations prevalent in certain types of cancers
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Subscribe To Our Newsletter & Stay Updated
